1-7 of 7
Lode J. Swinnen, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Thomas J. Kipps, M.D., Ph.D, Lode J. Swinnen, MD, William G. Wierda, MD, PhD, Jeffrey Alan Jones, MD, MPH, Steven E. Coutre, MD, Mitchell R Smith, MD, PhD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2011) 118 (21): 3904.
https://doi.org/10.1182/blood.V118.21.3904.3904
Published: 2011
Journal Articles

IGHV Mutational Status Is Prognostic in Del(11q) and Del(17p) Chronic Lymphocytic Leukemia

Douglas Edward Gladstone, MD, Amanda Blackford, Yvette L. Kasamon, Lode J. Swinnen, MD, Javier Bolanos Meade, MD, Christopher Gocke, Constance Griffin, M.D., Richard J. Jones
Journal: Blood
Blood (2011) 118 (21): 4598.
https://doi.org/10.1182/blood.V118.21.4598.4598
Published: 2011
Journal Articles

IgVH Mutational Status Is Prognostic In 13q Deletion (del) Chronic Lymphocytic Leukemia (CLL)

Douglas Edward Gladstone, Lode J. Swinnen, MD, Christopher Gocke, Amanda Blackford, Constance A. Griffin, Richard J. Jones, MD
Journal: Blood
Blood (2010) 116 (21): 2419.
https://doi.org/10.1182/blood.V116.21.2419.2419
Published: 2010
Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA
Journal: Blood
Blood (2010) 116 (21): 2362.
https://doi.org/10.1182/blood.V116.21.2362.2362
Published: 2010
Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Lode J. Swinnen, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD
Journal: Blood
Blood (2010) 116 (21): 2455.
https://doi.org/10.1182/blood.V116.21.2455.2455
Published: 2010
Journal Articles

Phase II Study of High Dose Outpatient Cyclophosphamide and Rituximab, without Stem Cell Support, for Low Grade and Mantle Cell Lymphoma.

Lode J. Swinnen, MD, Richard J. Jones, MD, Miah Jung, BS, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2006) 108 (11): 2741.
https://doi.org/10.1182/blood.V108.11.2741.2741
Published: 2006
Journal Articles

Dose Finding Trial of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Ian W. Flinn, MD, Ph D., Brad S. Kahl, MD, Eric Frey, Ph D, Jesus A. Bianco, MD, Richard J. Hammes, R Ph, Lynn S. Billing, Lode J. Swinnen, MD, George Sgouros, Ph D, Richard L. Wahl, MD
Journal: Blood
Blood (2004) 104 (11): 897.
https://doi.org/10.1182/blood.V104.11.897.897
Published: 2004